BCBenilde Cosmi

Benilde Cosmi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benilde Cosmi has a total of 230 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CO013 | INDICATIONS AND OUTCOMES OF OPTIONAL INFERIOR CAVA FILTERS IN CANCER-ASSOCIATED THROMBOSIS AND IN NON CANCER PATENTS WITH VENOUS THROMBOEMBOLISM

    by Benilde Cosmi

    Introduction. Inferior vena cava filters (IVCF) are an option in patients with acute venous thromboembolism (VTE) with a coexisting absolute contraindication to anticoagulation to reduce the risk of fatal pulmonary embolism. Cancer patients are at high risk of both VTE, bleeding, and death, and the benefits of IVCF insertion in cancer-associated thrombosis (CAT) are uncertain.Objectives: to investigate the indications for optional IVCF, their retrieval rates, and complications in patients with CAT compared to cancer-free patients with VTE.Design: retrospective cohort study in two tertiary care hospitals.Participants. consecutive patients diagnosed with symptomatic VTE and undergoing optional IVCF placement from 2018 and 2022 and a follow-up of two years.Primary outcome measures. IVCF retrieval rates and complications, thromboembolic complications, and short (within 30 days) and long-term (24 months) all-cause mortality.Results. 334 patients (171 women—53%, median age 75.5 years) were included. IVCF was inserted pre-operatively in 156 patients (47%), of whom 107 (68%) had CAT. Non-preoperative IVCF was inserted in 178 patients, of whom 74 (41%) had CAT, 136 (76%) had major bleeding, and 41 (12.3%) were at high bleeding risk. IVFC was removed in 135 patients (40.4%), with a similar rate of filter thrombosis (13.5% vs. 10.4%; p=0.73) and removal (41% vs. 46%; p=0.9) among cancer and cancer-free patients. VTE recurrence or progression was similar between cancer and non-cancer patients (13% vs 12%) over 24 months. Non-preoperative IVCF was associated with a higher mortality rate at 30 days after IVCF insertion in both CAT and cancer-free patients. All-cause mortality between 31 days and 24 months after filter insertion was higher in cancer than non-cancer patients (p=0.0001).Conclusions. Thrombotic complications after IVCF insertion were similar in CAT and non-cancer patients. Short-term mortality was higher after nonoperative than after preoperative filter insertion in both CAT and cancer-free patients. However, patients with CAT had a higher long-term all-cause mortality, regardless of IVCF indication and removal.

  • Open Access

    Home-based intravenous iloprost by portable elastomeric pump in chronic limb-threatening ischemia: A pilot study

    by Michelangelo Sartori, Elisabetta Favaretto, Elisa Zanata, Sofia Cavara, Alessia Libra, Alessia Sonetto, Enrico Gallitto, Mauro Gargiulo, Benilde Cosmi

    Background: Iloprost has been proposed as a pharmacological option for patients with chronic limb-threatening ischemia (CLTI) in whom revascularization is either not feasible or has been unsuccessful. This pilot study aimed to evaluate the safety and effectiveness of intravenous iloprost at low infusion rates via an elastomeric pump at home (EP-iloprost) versus higher infusion rates via a peristaltic pump in the hospital (PP-iloprost) for 1 year. Methods: This was a cohort study conducted in ‘no-option’ patients for revascularization with CLTI. The follow-up was 3 years. The primary endpoint was the incidence of drug-related adverse events (AEs); the secondary outcome was the composite of all-cause death and major amputations. Results: We enrolled 56 patients who received EP-iloprost as a pilot study. Their outcomes were compared with a cohort of 48 patients who had received PP-iloprost. AEs were reported in 15 (31.3%) patients who received PP-iloprost and in eight (14.3%) who received EP-iloprost ( p = 0.038), with the exposure-adjusted incidence rate being 22.7/100 patient-years in the PP-iloprost group and 8.3/100 patient-years in the EP-iloprost group. Although the two cohorts were not well-suited for comparison due to age differences, there were seven (12.5%) deaths and four (7.1%) major amputations in the EP cohort compared with 11 (22.9%) deaths and 13 (27.1%) major amputations in the PP cohort. Conclusions: These hypothesis-generating data suggest that low-rate infusion of EP-iloprost at home is better tolerated and potentially more effective than high-rate infusion with PP in a hospital setting.

  • Open Access

    D-dimer levels in patients with acute venous thromboembolism and occult cancer: the DD-Neo study

    by Benilde Cosmi, Elisa Lasala, Laura Borgese, Stefania Cavazza, Cristina Legnani, Michelangelo Sartori, Gualtiero Palareti

    Cancer is associated with a prothrombotic state and venous thromboembolism (VTE) can be the first manifestation of occult cancer. However, no impact on survival of extensive cancer screening in VTE has been demonstrated. Limited data are available on the association between D-dimer (DD), a non-specific marker of activation of coagulation, at VTE diagnosis and occult cancer. The objective is to investigate whether high DD levels at VTE diagnosis are associated with subsequent cancer development. The study design is a retrospective cohort study conducted in a single tertiary care hospital from 2008 to 2018. The participants were consecutive patients diagnosed with symptomatic VTE and without known overt cancer who underwent routine clinical evaluation and laboratory tests. In case of abnormal findings, further targeted tests were performed. The primary outcome measures were cancer development within 12 months of VTE diagnosis. 843 patients (413 women—49%, median age 67.3 years; 10 lost to follow-up—1.2%) were included, of whom 567 (67%) had unprovoked VTE. Median DD was 2,750 ng/mL (range 30–45,320) and DD was above 8,000 ng/mL in 151 patients (18%). During follow-up, 37 patients (all above 60 years) developed new cancers (4.6 percent patient years; 95%CI 3.3–6.3). Multivariate regression showed that age above 60 years (Hazard Ratio–HR 11.7; 95%CI 1.58–86.6; p = 0.016) and DD above 8,000 ng/mL (HR: 2.5; 95%CI 1.22–5.24; p = 0.012) were independently associated with subsequent cancer development. Patients older than 60 years at VTE diagnosis may deserve extensive screening for occult cancer, and DD above 8000 ng/mL may be an index of occult cancer.


  • Open Access

    A comparison of the effects of direct oral anticoagulants versus vitamin K antagonists and antiplatelet agents on the timing and outcomes of hip fracture surgery in patients older than 65 years: the ORTHO-GER-DOAC study

    by Emilio Martini, Rossella Tozzi, Giulia Annessi, Laura Borgese, Maria Lia Lunardelli, Calogero Alfonso, Caternicchia Filippo, Elvira Grandone, Benilde Cosmi

    Introduction: The use of direct oral anticoagulants (DOACs) may delay surgery in older hip fracture patients. Aim: To assess whether preoperative DOAC activity measurement enables surgery within 48 h in hip fracture patients at a similar prevalence compared to patients receiving other antithrombotics or no antithrombotics. Methods: A retrospective observational cohort study of hip fracture patients older than 65 years admitted to three Orthogeriatrics units in Italy from 2015 to 2022 was conducted. At admission, demographical and comorbid conditions were recorded, and antithrombotics were stopped. Patients on vitamin K antagonists (VKAs) underwent international normalized ratio (INR) assessments and received vitamin K to achieve an INR below 1.5. Patients receiving DOACs who were enrolled before 2018 underwent daily drug testing, and surgery was performed only after DOAC levels were near or below trough levels. Hours from hospital admission to surgery, perioperative total blood loss, major bleeding and mortality at 90 days were recorded. Results: Amongst the 747 patients (median age 85 years; M/F: 192/555), the prevalence of surgery within 48 h was significantly lower amongst patients receiving DOACs (47%) than amongst patients receiving antiplatelet agents (77%) and patients receiving no antithrombotic agents (73%). Preoperative DOAC measurements significantly delayed the time to surgery (median 51 vs. 42 h: P < 0.05). The major bleeding and mortality rates at 90 days did not differ based on the type of antithrombotics used. The degree of perioperative blood loss was greater in patients receiving DOACs, regardless of drug measurement, than in patients taking other antithrombotics. Conclusions: DOAC measurement may delay hip fracture surgery, as even low presurgical levels of DOACs are associated with greater perioperative blood loss.


  • Semi-empirical Anticoagulation Model (SAM): Dose prediction during warfarin therapy

    by Marco Bontempi, Laura Borgese, Andrea Visani, Gianluca Giavaresi, Benilde Cosmi


  • Transitioning between therapeutic anticoagulants: a clinicians guide to switching patients to or from DOAC therapy

    by Benilde Cosmi, Michelangelo Sartori

    IntroductionThe transition to or from direct oral anticoagulants (DOACs) is common in clinical practice.Areas coveredA literature search was conducted on PubMed, Google Scholar, and UpToDate up to March 2024 for conditions and approaches for transitioning from one agent to the other. No randomized clinical trials were retrieved except for two studies regarding switching to DOAC in well-conducted vitamin K antagonist (VKA) therapy. A narrative review was conducted addressing the conditions for switching from one agent to the other, such as thromboembolic events and major bleeding during anticoagulation, development or worsening of kidney or liver failure, initiation of interfering drugs, adverse events such as allergic reactions, frailty, patients' preferences, and affordability. During transitions from one anticoagulant to the other, the risk of both thromboembolic and bleeding complications should be minimized. The current approaches for such transitions are derived from those employed in clinical trials evaluating DOAC and from product information.Expert opinionMany uncertainties remain regarding those circumstances requiring a change in anticoagulant strategies, as they lack evidence-based guidance. It can be envisaged that the problem of switching to and from DOAC will need additional studies especially addressing the conditions and the best approach to such transitions.


  • Open Access

    Padua Prediction Score and Hospital-Acquired Proximal and Isolated Distal Deep Vein Thrombosis in Symptomatic Patients

    by Michelangelo Sartori, Miriam Fiocca, Mario Soldati, Laura Borgese, Elisabetta Favaretto, Benilde Cosmi

    Background: Hospital-acquired deep vein thrombosis (DVT) is an important cause of morbidity and mortality. Objectives: The purpose of this study was to evaluate the prevalence of proximal lower limb DVT and isolated distal DVT (IDDVT) and their relationship to the Padua Prediction Score (PPS) in acutely ill, hospitalized patients. Methods: In a single-center cross-sectional study, all inpatients from medical departments with suspected lower-extremity DVT were evaluated with whole-leg ultrasonography during 183 days from 2016 to 2017. Results: Among the 505 inpatients (age 78.0 ± 13.3, females 59.2%) from medical departments, 204 (40.2%) had PPS ≥ 4, but only 54.4% of them underwent pharmacological thrombo-prophylaxis. Whole-leg ultrasonography detected 47 proximal DVTs (9.3%) and 65 IDDVTs (12.8%). Proximal DVT prevalence was higher in patients with high PPS vs. those with low PPS (12.7% vs. 7.0% p = 0.029, respectively), whereas IDDVT prevalence was similar in patients with high and low PPS (14.7% vs. 11.6% p = 0.311, respectively). The area under the receiver operating curve (AUC) for the PPS was 0.62 ± 0.03 for all DVTs, 0.64 ± 0.04 for proximal DVTs, and 0.58 ± 0.04 for IDDVTs. Conclusions: In hospitalized patients, IDDVT had similar prevalence regardless of PPS risk stratification. Adherence to thrombo-prophylaxis in patients was still far from optimal.


  • Sex Differences in Clinical Presentation of Lower Extremity Deep Vein Thrombosis

    by Benilde Cosmi, Laura Borgese, Cristina Legnani, Michelangelo Sartori, Gualtiero Palareti

    Background: Differences between men and women in the clinical features and extent of lower limb deep vein thrombosis (DVT) may influence DVT diagnostic algorithms involving pretest clinical probability (PTP) assessment, D-dimer, and compression ultrasonography (CUS). Aims: To assess differences in DVT clinical presentation between men and women and their effect on PTP and D-dimer. Methods: We conducted a retrospective study in outpatients referred for suspected DVT of the lower limbs to our vascular emergency department from January 2005 to December 2019. Patients underwent PTP assessment with the Wells score, D-dimer testing, and CUS. Results: More women were referred for suspected DVT than men (M/F: 1,785/2,821; F: 61.4%; p < 0.0001). Women were older than men (median age: 71 vs. 67 years; p = 0.0001), DVT was diagnosed in 436 patients (9.4%) but in more men than women (M: 210 [11.8%] vs. F: 226 [8%]; p = 0.0002), with more proximal DVT in men than women (M: 131 7.3% vs. F: 124 [4.4%]; p = 0.00021). PTP was more likely in men (355 [19.9%]) than women (455 [16.2%]) ( p = 0.0011); more men had swelling in the entire limb, increased calf circumference by >3 cm compared with the contralateral limb, and pitting edema, than women. D-dimer levels (available in 65% of patients) were more frequently positive in women with DVT than in men (94.6% vs. 85.7%; p = 0.016). However, a positive D-dimer and/or likely PTP was similarly frequent in men (92%) and women (96%) with DVT. Conclusions: More women than men are referred for suspected DVT, and men have a higher prevalence of proximal DVT. However, current algorithms for DVT diagnosis perform similarly in men and in women.


  • Open Access

    D-Dimer Levels in Patients with Acute Venous Thromboembolism and Occult Cancer: TheDd-Neo Study

    by Benilde Cosmi, Elisa Lasala, Laura Borgese, Stefania Cavazza, Cristina Legnani, Michelangelo Sartori, Gualtiero Palareti

    Introduction: Cancer is associated with a prothrombotic state and venous thromboembolism (VTE) can be the first manifestation of occult cancer. However, no impact on survival of extensive cancer screening in VTE has been demonstrated. Limited data are available on the association between D-dimer (DD), a non specific marker of activation of coagulation, at VTE diagnosis and occult cancer. Objectives: to investigate whether DD levels at VTE diagnosis are associated with subsequent cancer development. Design: retrospective cohort conducted in a single tertiary care hospital from 2008 to 2018. Participants: consecutive patients diagnosed with symptomatic VTE and without known overt cancer underwent routine clinical evaluation and laboratory tests. In case of abnormal findings, further targeted tests were performed. Primary outcome measures : cancer development within 12 months since VTE diagnosis. Results: 843 patients (413 women - 49%, median age 67.3 years; 10 lost to follow-up -1.2%) were included of whom 567 (67%) had unprovoked VTE. Median DD was 2,750 ng/mL (range 30-45,320) and DD was above 8,000 ng/mL in 151 patients (18%). During follow-up, 37 patients (all above 60 years) developed new cancers (4.6 percent patient years; 95% Confidence Intervals-CI:3.3-6.3). Multivariate regression showed that age above 60 years (Hazard Ratio-HR 11.7; 95% CI: 1.58-86.6; p=0.016) and DD above 8,000 ng/mL (HR: 2.5 95% CI:1.22-5.24; p=0.012) were independently associated with subsequent cancer development. Conclusions: Patients older than 60 years at VTE diagnosis may deserve extensive screening for occult cancer, and DD above 8,000 ng/mL may be a sign an index of occult cancer.

  • Open Access

    Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention

    by Anna Falanga, Domenica Lorusso, Nicoletta Colombo, Gennaro Cormio, Benilde Cosmi, Giuseppa Scandurra, Vanna Zanagnolo, Marco Marietta

    The prevention and appropriate management of venous thromboembolism in cancer patients is of paramount importance. However, the literature data report an underestimation of this major problem in patients with gynecological cancers, with an inconsistent venous thromboembolism risk assessment and prophylaxis in this patient setting. This narrative review provides a comprehensive overview of the available evidence regarding the management of venous thromboembolism in cancer patients, focusing on the specific context of gynecological tumors, exploring the literature discussing risk factors, risk assessment, and pharmacological prophylaxis. We found that the current understanding and management of venous thromboembolism in gynecological malignancy is largely based on studies on solid cancers in general. Hence, further, larger, and well-designed research in this area is needed.